Moderna, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US60770K1079
USD
53.54
2.26 (4.41%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Halozyme Therapeutics, Inc.
Amgen, Inc.
Illumina, Inc.
Gilead Sciences, Inc.
Moderna, Inc.
Bio-Techne Corp.
BioMarin Pharmaceutical, Inc.
Biogen, Inc.
Elanco Animal Health, Inc.
Vaxcyte, Inc.
Immunovant, Inc.

Why is Moderna, Inc. ?

1
Flat results in Dec 25
  • NET SALES(HY) At USD 1,694 MM has Grown at -40.1%
  • INTEREST(Q) Highest at USD 8 MM
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 50.25%, its profits have risen by 20.8%
3
High Institutional Holdings at 80.65%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
  • The stock has generated a return of 50.25% in the last 1 year, much higher than market (S&P 500) returns of 13.68%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you hold?

  1. Overall Portfolio exposure to Moderna, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Moderna, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Moderna, Inc.
56.69%
-0.96
68.29%
S&P 500
13.68%
0.71
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
19.33%
EBIT Growth (5y)
-215.19%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.59
Sales to Capital Employed (avg)
0.38
Tax Ratio
1.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.65%
ROCE (avg)
68.02%
ROE (avg)
25.33%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.43
EV to EBIT
-5.15
EV to EBITDA
-5.42
EV to Capital Employed
4.60
EV to Sales
8.15
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-89.33%
ROE (Latest)
-32.62%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -1,873 MM

NET PROFIT(HY)

Higher at USD -1,026 MM

RAW MATERIAL COST(Y)

Fallen by -37.81% (YoY

NET SALES(Q)

At USD 678 MM has Grown at 21.51%

-11What is not working for the Company
NET SALES(HY)

At USD 1,694 MM has Grown at -40.1%

INTEREST(Q)

Highest at USD 8 MM

Here's what is working for Moderna, Inc.

Operating Cash Flow
Highest at USD -1,873 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit
Higher at USD -1,026 MM
than preceding 12 month period ended Dec 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Net Sales
At USD 678 MM has Grown at 21.51%
over average net sales of the previous four periods of USD 558 MM
MOJO Watch
Near term sales trend is positive

Net Sales (USD MM)

Raw Material Cost
Fallen by -37.81% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at USD 67 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Depreciation
At USD 67 MM has Grown at 28.85%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (USD MM)

Here's what is not working for Moderna, Inc.

Interest
At USD 8 MM has Grown at inf%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Interest
Highest at USD 8 MM
in the last five periods and Increased by inf% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)